Bacillary Dysentery (Shigellosis)-Pipeline Review, H1 2017

Bacillary Dysentery (Shigellosis)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9038IDB
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Bacillary Dysentery (Shigellosis)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacillary Dysentery (Shigellosis)-Pipeline Review, H1 2017, provides an overview of the Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline landscape.

Shigella Infections (Shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps and fever. Predisposing factors include eating contaminated food, age, international travelers and homosexual men. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacillary Dysentery (Shigellosis)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 3 and 1 molecules, respectively.

Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bacillary Dysentery (Shigellosis) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacillary Dysentery (Shigellosis)-Overview

Bacillary Dysentery (Shigellosis)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bacillary Dysentery (Shigellosis)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacillary Dysentery (Shigellosis)-Companies Involved in Therapeutics Development

Akthelia Pharmaceuticals Ltd

GlaxoSmithKline Plc

Microbiotix Inc

Protein Potential LLC

Bacillary Dysentery (Shigellosis)-Drug Profiles

(shigella + typhoid) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKT-10081-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GVXNSD-133-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KKL-35-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-599-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SE-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF2a-TT15-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella [serotype 2a] (whole cell) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella [strain 53G] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Shigetec-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WRSs-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WRSs-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacillary Dysentery (Shigellosis)-Dormant Projects

Bacillary Dysentery (Shigellosis)-Discontinued Products

Bacillary Dysentery (Shigellosis)-Product Development Milestones

Featured News & Press Releases

Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine

Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates

Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease

Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Bacillary Dysentery (Shigellosis)-Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017

Bacillary Dysentery (Shigellosis)-Pipeline by GlaxoSmithKline Plc, H1 2017

Bacillary Dysentery (Shigellosis)-Pipeline by Microbiotix Inc, H1 2017

Bacillary Dysentery (Shigellosis)-Pipeline by Protein Potential LLC, H1 2017

Bacillary Dysentery (Shigellosis)-Dormant Projects, H1 2017

Bacillary Dysentery (Shigellosis)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Akthelia Pharmaceuticals Ltd, GlaxoSmithKline Plc, Microbiotix Inc, Protein Potential LLC

Bacillary Dysentery (Shigellosis) Therapeutic Products under Development, Key Players in Bacillary Dysentery (Shigellosis) Therapeutics, Bacillary Dysentery (Shigellosis) Pipeline Overview, Bacillary Dysentery (Shigellosis) Pipeline, Bacillary Dysentery (Shigellosis) Pipeline Assessment

select a license
Single User License
USD 2000 INR 141940
Site License
USD 4000 INR 283880
Corporate User License
USD 6000 INR 425820

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com